The effect of concomitant proton pump inhibitor and cabozantinib on the outcomes of patients with metastatic renal cell carcinoma.

CONCLUSION: In line with the pharmacologic data, the concomitant use of PPI does not significantly impact the efficacy or safety of cabozantinib in patients with mRCC.
IMPLICATIONS FOR CLINICAL PRACTICE: Proton Pump Inhibitors (PPI) are some of the most prescribed drugs worldwide and they can interact with other oral administered drugs such as Cabozantinib, potentially reducing their efficacy. Cabozantinib is a current therapeutic standard in mRCC, frequently administered with PPI. At the present time there is no evidence regarding the effect of PPIs on Cabozantinib's efficacy and safety in mRCC patients. We hereby demonstrate that the concomitant administration of PPI during Cabozantinib treatment in mRCC patients does neither modify the residual concentration of Cabozantinib nor has a relevant effect on its safety and efficacy in a real life context.
PMID: 33554383 [PubMed - as supplied by publisher]

Source: The Oncologist - February 8, 2021 Category: Cancer & Oncology Authors: Rassy E, Cerbone L, Auclin E, Benchimoll-Zouari A, Flippot R, Alves Costa Silva C, Colomba E, Geraud A, Guida A, Mir O, Combarel D, Paci A, Escudier B, Albiges L Tags: Oncologist Source Type: research